Plinabulin, administered intraperitoneally at doses ranging from 0 mg/kg to 15 mg/kg to female CDF1 and C3H/He mice, results in a time- and dose-dependent reduction in tumor perfusion. KHT sarcoma exhibits a higher sensitivity to Plinabulin's anti-tumor effects compared to C3H tumors, with both models showing an enhanced response to radiation^[3].

Plinabulin (NPI-2358), in concentrations ranging from 2-200 nM and applied for 30 minutes to HUVECs cells, acts as a potent anti-tumor agent. It effectively induces tubulin depolymerization and increases monolayer permeability, showing activity against multidrug-resistant tumor cell lines with IC50 values of 18 nM for DU 145 cells, 13 nM for PC-3 cells, 14 nM for MDA-MB-231 cells, 18 nM for NCI-H292 cells, and 11 nM for Jurkat leukemia cells^[1].